health
Anticonvulsant Effect
An anticonvulsant effect refers to reducing the occurrence or severity of seizures. It describes an outcome related to seizure control or prevention, rather than a general calming, sleep, or relaxation effect.
See how the Anticonvulsant Effect is presented as a health topic, with focused information for easier reading.
These are research findings, not promises. Most options have little evidence, and results differ from person to person.
What may help
None of these options has good evidence yet. Best evidence first.
1 option:1 not tested in people
AcupuncturepracticeNot tested in people
Only tested in animals, cells or theory. Results like these often do not carry over to people.
The one study found a benefit.
Acupuncture has been suggested as an adjunctive therapy for drug-resistant epilepsy that may reduce seizure frequency, although effects vary and it is not curative; human evidence has not established this effect.
Open the Acupuncture page
The expert view shows every study, dose protocol and source.
What may help
Linked to improving it1 listedStart here
The best we have, but the evidence is still weak
- →PracticesAcupunctureCertaintyLowSourceTheoretical1 other source
Acupuncture has been suggested as an adjunctive therapy for drug-resistant epilepsy that may reduce seizure frequency, although effects vary and it is not curative; human evidence has not established this effect.
Open AcupunctureStudy result
Acupuncture may reduce seizure frequency in people with drug-resistant epilepsy as an adjunctive therapy, though effects vary and are not curative.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
An anticonvulsant effect refers to reducing the occurrence or severity of seizures. It describes an outcome related to seizure control or prevention, rather than a general calming, sleep, or relaxation effect.
The evidence under this label may involve different interventions and clinical contexts. For example, findings for CBD (Cannabidiol), Vitamin B6 (Pyridoxine), Melatonin, and Magnesium should not be treated as interchangeable; evidence for intravenous magnesium sulfate in severe preeclampsia and eclampsia does not establish oral magnesium as a general antiepileptic.
How interventions help
Interventions associated with anticonvulsant effects differ substantially in setting, timing, and intended use. CBD (Cannabidiol) was evaluated over 14 weeks, with a treatment ratio of 0.70 (95% CI 0.62–0.80), p<0.0001. This represents the clearest human-supported signal in the group, although the findings should not be generalized beyond the populations and treatment circumstances studied.
Other approaches are more context-dependent. Vitamin B6 (Pyridoxine) is described as diagnosis- and route-specific under specialist supervision rather than as a general self-directed intervention. Melatonin was studied at 3 mg/day for 8 weeks, with a mean change of 32.33 ± 9.24 with melatonin versus 5.58 ± 14.28 with placebo; p=.002. Magnesium has an established role as intravenous magnesium sulfate in acute obstetric treatment for preventing and treating seizures associated with severe preeclampsia and eclampsia, but this does not establish oral magnesium as a general antiepileptic.
Several options remain preliminary or are tied to specialized models. MCT Oil is described as part of a clinician-supervised MCT ketogenic diet, where it promotes ketone production and may reduce seizure frequency in some patients with drug-resistant epilepsy. Creatine was used for 3 days pre-hypoxia in a model involving electrographic seizures, while Saffron Extract produced an immediate effect in acute animal research and did not require daily use. Taurine is described as a chronic intervention with proposed GABAergic modulation and membrane stabilization, but its clinical evidence is limited. These differences mean that results from acute, animal, hypoxia-related, or specialist-supervised settings should not be treated as interchangeable with evidence from ongoing human treatment.
Choosing guidance
These options are not interchangeable. CBD (Cannabidiol) is the only listed option marked as having human evidence, making it the most directly applicable choice when relevance to people is the main consideration. Its evidence comes from studies lasting weeks rather than an immediate-use setting, so it should not be interpreted as a rapid-onset option.
Vitamin B6 (Pyridoxine) is diagnosis- and route-specific and requires specialist supervision, while MCT Oil is described only as part of a clinician-supervised MCT ketogenic diet for some people with drug-resistant epilepsy. Magnesium has a narrower context: the evidence concerns monitored intravenous treatment for seizures associated with severe preeclampsia and eclampsia, and does not support treating oral magnesium as a general antiepileptic. These options therefore suit specialized clinical situations rather than broad self-directed use.
Melatonin, Creatine, Saffron Extract, and Taurine have limitations that affect how their findings can be applied. The listed melatonin evidence is short-term, Creatine relates to a brief pre-hypoxia setting, and Saffron Extract is based on animal research with an acute time course rather than human treatment. Taurine is described as requiring ongoing use, with limited clinical evidence. Saffron Extract is the only option identified with an immediate onset category, but that does not establish human effectiveness. Magnesium also has conflicting evidence, so its results require particular caution when comparing it with options supported by more directly applicable findings.